中国医药
中國醫藥
중국의약
CHINA MEDICINE
2012年
8期
955-957
,共3页
吕华荣%王峻%吴星%周滨音%戴学元%裴永恩
呂華榮%王峻%吳星%週濱音%戴學元%裴永恩
려화영%왕준%오성%주빈음%대학원%배영은
胶质瘤%苯妥英钠%药物浓度%高效液相色谱法
膠質瘤%苯妥英鈉%藥物濃度%高效液相色譜法
효질류%분타영납%약물농도%고효액상색보법
Glioblastoma%Phenytoin%Drug concentration%High performance liquid chromatography
目的 研究苯妥英钠对化学治疗耐药人胶质母细胞瘤细胞(8-MG-BA)内卡莫司汀、替尼泊苷积聚浓度的影响.方法 实验细胞分为5组,H4细胞组、8-MG-BA细胞组、8-MG-BA+苯妥英钠5 mg,/L组、8-MG-BA+苯妥英钠10 mg/L组、8-MG-BA+维拉帕米5 mg/L组.采用高效液相色谱法(HPLC)检测各组细胞内卡莫司汀、替尼泊苷积聚浓度.采用外标标准曲线法,以药物的质量浓度(C)为横坐标、峰面积(A)为纵坐标进行线性回归计算,并测定仪器精密度与方法回收率.结果 吸收1、3h后,H4细胞组细胞内卡莫司汀、替尼泊苷含量均高于8-MG-BA细胞组[吸收1h后卡莫司汀浓度:(1.75±0.05)mg/L比(0.31±0.03)mg/L,吸收3h后卡莫司汀浓度:(1.70±0.03)mg/L比(0.39±0.04)mg/L,吸收1h后替尼泊苷浓度:(1.18±0.03)mg/L比(0.42±0.03)mg/L,吸收3h后替尼泊苷浓度:(1.09±0.04)mg/L比(0.46±0.03)mg/L,均P＜0.01]；8-MG-BA+维拉帕米5 mg/L组、8-MG-BA+苯妥英钠5 mg/L组、8-MG-BA+苯妥英钠10 mg/L组细胞内卡莫司汀、替尼泊苷含量均高于8-MG-BA细胞组[吸收1h后卡莫司汀浓度:(0.56±0.04)mg/L、(1.10±0.12)mg/L、(1.37±0.04)mg/L比(0.31±0.03)mg/L,吸收3h后卡莫司汀浓度:(0.68±0.04)mg/L、(1.25±0.03)mg/L,(1.49±0.04)mg/L比(0.39±0.04)mg/L,吸收1h后替尼泊苷浓度:(0.50±0.03)mg/L、(0.59±0.03)mg/L、(0.95±0.04)mg/L比(0.42±0.03)mg/L,吸收3h后替尼泊苷浓度:(0.53±0.04)mg/L、(0.62±0.04)mg/L、(1.01±0.03)mg/L比(0.46±0.03)mg/L,均p＜0.01]；8-MG-BA+苯妥英钠5 mg/L组、8-MG-BA+苯妥英钠10 mg/L组细胞内卡莫司汀、替尼泊苷含量均高于8-MG-BA+维拉帕米5 mg/L组(P＜0.01)；8-MG-BA+苯妥英钠5 mg/L组细胞内卡莫司汀、替尼泊苷含量均低于8-MG-BA+苯妥英钠10 mg/L组(P＜0.05).当被测VM26及卡莫司汀质量浓度为0.05～5 mg/L时,其浓度与峰面积之间具有良好的线性关系.替尼泊苷回收率分别为(96±5)％、(100±4)％和(99±2)％；卡莫司汀回收率分别为(100±5)％、(99±4)％和(99±4)％,日内(24h)、日间(2d间)误差相对标准偏差分别为4.47％和4.96％(n=5).结论 苯妥英钠可以增加化学治疗耐药8-MG-BA细胞内卡莫司汀、替尼泊苷的积聚浓度,并与剂量有关.
目的 研究苯妥英鈉對化學治療耐藥人膠質母細胞瘤細胞(8-MG-BA)內卡莫司汀、替尼泊苷積聚濃度的影響.方法 實驗細胞分為5組,H4細胞組、8-MG-BA細胞組、8-MG-BA+苯妥英鈉5 mg,/L組、8-MG-BA+苯妥英鈉10 mg/L組、8-MG-BA+維拉帕米5 mg/L組.採用高效液相色譜法(HPLC)檢測各組細胞內卡莫司汀、替尼泊苷積聚濃度.採用外標標準麯線法,以藥物的質量濃度(C)為橫坐標、峰麵積(A)為縱坐標進行線性迴歸計算,併測定儀器精密度與方法迴收率.結果 吸收1、3h後,H4細胞組細胞內卡莫司汀、替尼泊苷含量均高于8-MG-BA細胞組[吸收1h後卡莫司汀濃度:(1.75±0.05)mg/L比(0.31±0.03)mg/L,吸收3h後卡莫司汀濃度:(1.70±0.03)mg/L比(0.39±0.04)mg/L,吸收1h後替尼泊苷濃度:(1.18±0.03)mg/L比(0.42±0.03)mg/L,吸收3h後替尼泊苷濃度:(1.09±0.04)mg/L比(0.46±0.03)mg/L,均P＜0.01]；8-MG-BA+維拉帕米5 mg/L組、8-MG-BA+苯妥英鈉5 mg/L組、8-MG-BA+苯妥英鈉10 mg/L組細胞內卡莫司汀、替尼泊苷含量均高于8-MG-BA細胞組[吸收1h後卡莫司汀濃度:(0.56±0.04)mg/L、(1.10±0.12)mg/L、(1.37±0.04)mg/L比(0.31±0.03)mg/L,吸收3h後卡莫司汀濃度:(0.68±0.04)mg/L、(1.25±0.03)mg/L,(1.49±0.04)mg/L比(0.39±0.04)mg/L,吸收1h後替尼泊苷濃度:(0.50±0.03)mg/L、(0.59±0.03)mg/L、(0.95±0.04)mg/L比(0.42±0.03)mg/L,吸收3h後替尼泊苷濃度:(0.53±0.04)mg/L、(0.62±0.04)mg/L、(1.01±0.03)mg/L比(0.46±0.03)mg/L,均p＜0.01]；8-MG-BA+苯妥英鈉5 mg/L組、8-MG-BA+苯妥英鈉10 mg/L組細胞內卡莫司汀、替尼泊苷含量均高于8-MG-BA+維拉帕米5 mg/L組(P＜0.01)；8-MG-BA+苯妥英鈉5 mg/L組細胞內卡莫司汀、替尼泊苷含量均低于8-MG-BA+苯妥英鈉10 mg/L組(P＜0.05).噹被測VM26及卡莫司汀質量濃度為0.05～5 mg/L時,其濃度與峰麵積之間具有良好的線性關繫.替尼泊苷迴收率分彆為(96±5)％、(100±4)％和(99±2)％；卡莫司汀迴收率分彆為(100±5)％、(99±4)％和(99±4)％,日內(24h)、日間(2d間)誤差相對標準偏差分彆為4.47％和4.96％(n=5).結論 苯妥英鈉可以增加化學治療耐藥8-MG-BA細胞內卡莫司汀、替尼泊苷的積聚濃度,併與劑量有關.
목적 연구분타영납대화학치료내약인효질모세포류세포(8-MG-BA)내잡막사정、체니박감적취농도적영향.방법 실험세포분위5조,H4세포조、8-MG-BA세포조、8-MG-BA+분타영납5 mg,/L조、8-MG-BA+분타영납10 mg/L조、8-MG-BA+유랍파미5 mg/L조.채용고효액상색보법(HPLC)검측각조세포내잡막사정、체니박감적취농도.채용외표표준곡선법,이약물적질량농도(C)위횡좌표、봉면적(A)위종좌표진행선성회귀계산,병측정의기정밀도여방법회수솔.결과 흡수1、3h후,H4세포조세포내잡막사정、체니박감함량균고우8-MG-BA세포조[흡수1h후잡막사정농도:(1.75±0.05)mg/L비(0.31±0.03)mg/L,흡수3h후잡막사정농도:(1.70±0.03)mg/L비(0.39±0.04)mg/L,흡수1h후체니박감농도:(1.18±0.03)mg/L비(0.42±0.03)mg/L,흡수3h후체니박감농도:(1.09±0.04)mg/L비(0.46±0.03)mg/L,균P＜0.01]；8-MG-BA+유랍파미5 mg/L조、8-MG-BA+분타영납5 mg/L조、8-MG-BA+분타영납10 mg/L조세포내잡막사정、체니박감함량균고우8-MG-BA세포조[흡수1h후잡막사정농도:(0.56±0.04)mg/L、(1.10±0.12)mg/L、(1.37±0.04)mg/L비(0.31±0.03)mg/L,흡수3h후잡막사정농도:(0.68±0.04)mg/L、(1.25±0.03)mg/L,(1.49±0.04)mg/L비(0.39±0.04)mg/L,흡수1h후체니박감농도:(0.50±0.03)mg/L、(0.59±0.03)mg/L、(0.95±0.04)mg/L비(0.42±0.03)mg/L,흡수3h후체니박감농도:(0.53±0.04)mg/L、(0.62±0.04)mg/L、(1.01±0.03)mg/L비(0.46±0.03)mg/L,균p＜0.01]；8-MG-BA+분타영납5 mg/L조、8-MG-BA+분타영납10 mg/L조세포내잡막사정、체니박감함량균고우8-MG-BA+유랍파미5 mg/L조(P＜0.01)；8-MG-BA+분타영납5 mg/L조세포내잡막사정、체니박감함량균저우8-MG-BA+분타영납10 mg/L조(P＜0.05).당피측VM26급잡막사정질량농도위0.05～5 mg/L시,기농도여봉면적지간구유량호적선성관계.체니박감회수솔분별위(96±5)％、(100±4)％화(99±2)％；잡막사정회수솔분별위(100±5)％、(99±4)％화(99±4)％,일내(24h)、일간(2d간)오차상대표준편차분별위4.47％화4.96％(n=5).결론 분타영납가이증가화학치료내약8-MG-BA세포내잡막사정、체니박감적적취농도,병여제량유관.
Objective To investigate the concentration of carmustine and teniposidc in glioblastoma cell line 8-MG-BA and H4 after incubated in different concentrations of Phenytoin (PHT)in vitro.Methods After treatment with phenytoin on different concentrations,intracellular concentration of carmustine and teniposide in H4 and 8-MG-BA cell line was determined by high efficiency liquid chromatography method in 60 and 120 minutes.Verapamil was used in control group.We used external standard calibration curve method to make linear regression calculations and the instrument precision and recovery rate of the methods were determined.Results The intracellular concentration of of bis-chloroethyltrosourea (BCNU)and teniposide (VM-26)in H4 cells was significantly higher than that in 8-MG-BA cells in control group (P ＜0.01).After being treated with PHT 5 mg/L,10 mg/L and VRP5 mg/l,the intracellular concentration of BCNU and VM-26 in 8-MG-BA cells was significantly higher than that in control group (P ＜ 0.05).The intracellular concentration of of BCNU and VM-26 in cells treated with PHT 5 mg/L.was significantly lower than that in PHT 10 mg/L treatde group (P ＜ 0.05).When the drug mass concentration was 0.05 to 5 mg/L,there was a good linear relationship between drug concentration and peak area.The recovery of VM-26 was (96 ±5)％,(100±4)％,(99 ±2)％ respectively.The recovery of VM-26 was (100 ± 5)％,(99 ±4)％,(99 ±4)％ respectively.The intra and inter-day RSD were less than 5％ (n =5).Conclusion PHT can increase the intracellrlar concentration of BCNU and VM-26 in 8-MG-BA cells.
